In short, Tepsivo is a group of supporters of progress and believers that pharmacovigilance can be a value-based field of healthcare. We believe that PV services have become too rigid and far too expensive, often even fuelled by inaccurate guidance by providers.

Since 2020, we have been modernizing the pharmacovigilance market by applying our unique automation solutions and transforming the industry. We have challenged the predominant business model of established PV companies who base their budgets on the number of hours or units such as ICSR volumes, creating a need for more time spent in order to invoice more. We saw that as a perverse incentive. And so we disrupted the field.

By 2022, we were the first company to offer a genuinely end-to-end PV solution, powered completely by fully in-house software and expert staff whose focus has always been on science instead of admin tasks. We then added an unmatched automation solution for literature monitoring and continued to integrate our tools, aiming for a fully streamlined process.

By 2024, we achieved our goal with the completion of Tepsivo OnePV as a fully digital, highly automated and completely integrated pharmacovigilance system having now supported globally over 50 pharma & biotech clients.

Today, with the backing of an established pharma services provider Clinigen Ltd., we are spearheading our PV revolution further and into the mainstream.

Visit our website: www.tepsivo.com